← ANALYST RATINGS · TIPRANKS
Precigen (PGEN): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $15.00, the highest $18.00, the lowest $12.00. The average is +134.9% from the last price of $6.38.
Analyst ratings 4
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.00 → $8.50−5.6% | Hold | +33.1% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $9.00 → $8.00−11.1% | Hold | +25.3% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.00 → $8.00−11.1% | Hold | +25.3% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.00 → $8.00−11.1% | Hold | +25.3% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.50 → $8.00−15.8% | Hold | +25.3% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.00 → $8.00−11.1% | Hold | +25.3% | Reiterated | 06.10.26on TipRanks 18:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 → $9.00+5.9% | Hold | +41.0% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.50 → $9.00+5.9% | Hold | +41.0% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.50 → $9.00+5.9% | Hold | +41.0% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.50 → $9.00+5.9% | Hold | +41.0% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.00 → $9.50+5.6% | Hold | +48.8% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.50 → $9.00+5.9% | Hold | +41.0% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.50 → $9.00+5.9% | Hold | +41.0% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.00 → $8.50+21.4% | Hold | +33.1% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $18.00 | Buy | +181.9% | Reiterated | 01.10.26on TipRanks 10:40 | −4.3%next day +3.3% · 5 days −8.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $8.50+6.2% | Hold | +33.1% | Reiterated | 01.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $8.50+6.2% | Hold | +33.1% | Reiterated | 01.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $8.50+6.2% | Hold | +33.1% | Reiterated | 01.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $8.50+6.2% | Hold | +33.1% | Reiterated | 01.10.26on TipRanks 00:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 | Hold | +25.3% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 | Hold | +25.3% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 | Hold | +25.3% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 | Hold | +25.3% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.50 | Hold | +33.1% | Reiterated | 29.09.26on TipRanks 00:06 | — | |
| Yuan Zhi★★★★★★★★★★#1180 · hits 41% · avg +20.7% | B. Riley Securities | $12.00 | Buy | +87.9% | Initiated | 25.09.26on TipRanks 05:00 | +0.1%next day +1.5% · 5 days +10.4% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $18.00 | Buy | +181.9% | Reiterated | 21.09.26on TipRanks 11:55 | −2.6%next day +2.5% · 5 days +2.4% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $7.00+7.7% | Hold | +9.6% | Reiterated | 20.08.26on TipRanks 00:06 | — | |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $9.00 → $11.00+22.2% | Buy | +72.3% | Reiterated | 14.05.26on TipRanks 21:25 | −2.7%next day −7.8% · 5 days −4.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Precigen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.00 at a price of $8.56 (+75.2%); now: $15.00 at $6.38 (+134.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 4 | 2 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.06 (from $0.05 to $0.09). Last quarter: $0.05.
Sales
Next quarter’s sales estimate — $72M (from $60M to $87M). Last quarter: $55M.
Best top-analyst consensus in the sector · Healthcare
About Precigen
- CEO: Helen Sabzevari
- Employees: 160
- 20374 Seneca Meadows Parkway, Germantown, MD, 20876, US
- www.precigen.com
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Data from the stock’s TipRanks forecast page, read 168 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗